Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth
Zomedica (OTCQB:ZOMDF), a veterinary health company, reported strong Q2 2025 financial results with revenue growing 14% to $7.0 million, marking its 18th consecutive quarter of year-over-year growth. The company achieved 67% gross margins and maintained a robust liquidity position of $59.1 million.
Key highlights include 86% growth in the Diagnostics segment, primarily driven by TRUFORMA platform adoption, and 21% growth in Consumable sales to $5.3 million. The Therapeutic Device segment, comprising PulseVet and Assisi products, grew 8% to $6.2 million. International sales increased by 13% year-over-year. Operating expenses decreased by $0.7 million, though the company reported a net loss of $7.4 million.
Zomedica (OTCQB:ZOMDF), un'azienda nel settore della salute veterinaria, ha riportato solidi risultati finanziari per il secondo trimestre 2025 con un fatturato in crescita del 14% a 7,0 milioni di dollari, segnando il 18° trimestre consecutivo di crescita anno su anno. L'azienda ha raggiunto margini lordi del 67% e ha mantenuto una solida posizione di liquidità pari a 59,1 milioni di dollari.
I punti salienti includono una crescita dell'86% nel segmento Diagnostica, principalmente trainata dall'adozione della piattaforma TRUFORMA, e una crescita del 21% nelle vendite di consumabili che hanno raggiunto 5,3 milioni di dollari. Il segmento Dispositivi Terapeutici, che comprende i prodotti PulseVet e Assisi, è cresciuto dell'8% raggiungendo 6,2 milioni di dollari. Le vendite internazionali sono aumentate del 13% su base annua. Le spese operative sono diminuite di 0,7 milioni di dollari, anche se l'azienda ha registrato una perdita netta di 7,4 milioni di dollari.
Zomedica (OTCQB:ZOMDF), una empresa de salud veterinaria, reportó sólidos resultados financieros en el segundo trimestre de 2025 con un crecimiento de ingresos del 14% hasta 7,0 millones de dólares, marcando su 18º trimestre consecutivo de crecimiento interanual. La compañía logró márgenes brutos del 67% y mantuvo una posición de liquidez sólida de 59,1 millones de dólares.
Los puntos clave incluyen un crecimiento del 86% en el segmento de Diagnósticos, impulsado principalmente por la adopción de la plataforma TRUFORMA, y un crecimiento del 21% en ventas de consumibles hasta 5,3 millones de dólares. El segmento de Dispositivos Terapéuticos, que incluye los productos PulseVet y Assisi, creció un 8% hasta 6,2 millones de dólares. Las ventas internacionales aumentaron un 13% interanual. Los gastos operativos disminuyeron en 0,7 millones, aunque la empresa reportó una pérdida neta de 7,4 millones de dólares.
Zomedica (OTCQB:ZOMDF)는 수의학 건강 회사로서 2025년 2분기 강력한 재무 실적을 보고했으며, 매출이 14% 증가하여 700만 달러를 기록하며 18분기 연속 전년 대비 성장세를 이어갔습니다. 회사는 67%의 총 이익률을 달성했으며, 5910만 달러의 견고한 유동성 위치를 유지했습니다.
주요 내용으로는 TRUFORMA 플랫폼 채택에 힘입어 진단 부문이 86% 성장했으며, 소모품 매출은 21% 증가하여 530만 달러를 기록했습니다. PulseVet 및 Assisi 제품을 포함하는 치료용 장치 부문은 8% 성장하여 620만 달러를 달성했습니다. 해외 매출은 전년 대비 13% 증가했습니다. 영업 비용은 70만 달러 감소했으나, 순손실은 740만 달러를 기록했습니다.
Zomedica (OTCQB:ZOMDF), une entreprise de santé vétérinaire, a annoncé de solides résultats financiers pour le deuxième trimestre 2025 avec une croissance du chiffre d'affaires de 14% à 7,0 millions de dollars, marquant son 18e trimestre consécutif de croissance annuelle. La société a atteint des marges brutes de 67% et maintenu une position de liquidité robuste de 59,1 millions de dollars.
Les points clés incluent une croissance de 86% dans le segment Diagnostics, principalement portée par l'adoption de la plateforme TRUFORMA, et une croissance de 21% des ventes de consommables à 5,3 millions de dollars. Le segment des dispositifs thérapeutiques, comprenant les produits PulseVet et Assisi, a progressé de 8% pour atteindre 6,2 millions de dollars. Les ventes internationales ont augmenté de 13% en glissement annuel. Les dépenses d'exploitation ont diminué de 0,7 million, bien que la société ait enregistré une perte nette de 7,4 millions de dollars.
Zomedica (OTCQB:ZOMDF), ein Unternehmen im Bereich der veterinärmedizinischen Gesundheit, meldete starke Finanzergebnisse für das zweite Quartal 2025 mit einem Umsatzwachstum von 14 % auf 7,0 Millionen US-Dollar, was das 18. aufeinanderfolgende Quartal mit Wachstum im Jahresvergleich markiert. Das Unternehmen erzielte Bruttomargen von 67 % und hielt eine solide Liquiditätsposition von 59,1 Millionen US-Dollar.
Zu den wichtigsten Highlights zählen ein 86%iges Wachstum im Diagnostiksegment, das hauptsächlich durch die Einführung der TRUFORMA-Plattform getrieben wurde, sowie ein 21%iges Wachstum bei den Verbrauchsmaterialverkäufen auf 5,3 Millionen US-Dollar. Das Segment Therapeutische Geräte, bestehend aus PulseVet- und Assisi-Produkten, wuchs um 8 % auf 6,2 Millionen US-Dollar. Die internationalen Verkäufe stiegen um 13 % im Jahresvergleich. Die Betriebsausgaben sanken um 0,7 Millionen US-Dollar, obwohl das Unternehmen einen Nettoverlust von 7,4 Millionen US-Dollar meldete.
- Revenue growth of 14% year-over-year to $7.0 million
- Strong gross margin of 67%
- Diagnostics segment revenue up 86%
- Consumable revenues increased 21% to $5.3 million
- International sales grew 13%
- Healthy liquidity position with $59.1 million in cash and securities
- Operating expenses reduced by $0.7 million in Q2
- Net loss of $7.4 million in Q2 2025
- Adjusted Non-GAAP EBITDA loss increased to $5.5 million from $5.2 million year-over-year
- Capital revenues remained flat at $1.7 million
- Research and development expenses increased 25%
- Selling and marketing expenses rose 19%
Insights
Zomedica shows solid revenue growth with strong margins, but operating losses continue despite cost-cutting efforts.
Zomedica's Q2 results demonstrate continued momentum with 14% year-over-year revenue growth to
The company's recurring revenue model is showing signs of traction, with consumable sales up
Despite these positive revenue indicators, Zomedica continues to operate at a significant loss. The quarterly net loss was
Management highlighted cost reduction initiatives that reduced operating expenses by
Liquidity remains strong with
Zomedica posts record year-over-year revenue for 18th straight quarter!
ANN ARBOR, MI / ACCESS Newswire / August 6, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2025.
"We are very pleased with the
"Through further expansion of our portfolio and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable usage as evidenced by
"International sales continue to grow, with sales up
"We are particularly pleased with the success of recent initiatives aimed at expanding our coverage and extending the use of our suite of products. During the quarter, we launched a national Equine Asthma registry which provides us with a low cost way to accumulate data to support expanded usage of our PulseVet system.
"To further strengthen the impact and reach of our products, we continue to work to identify gaps in market offerings, including upgrading and enhancing our current products to address changing needs and to provide better, faster, and more accurate performance. This can be seen through the recent launch of our enhanced TRUFORMA® T4 assay and a VetGuardian® onboarding app designed to help streamline the installation and integration process. We expect to roll out additional enhancements to our VetGuardian and TRUVIEW® platforms during the upcoming quarter.
"Gross margin, a key component of reaching profitability, came in at
"Internal cost reduction initiatives are well underway, as evidenced by our
"Based on the momentum we have created through the second quarter of the year, and supported by the strength of our balance sheet, we believe that we are well positioned to aggressively execute on our strategy to drive the accelerated adoption of our innovative portfolio on a global scale," concluded Mr. Heaton.
2025 Second Quarter Financial Highlights
Revenue for the second quarter of 2025 grew by
Revenue by Product Segment:
Diagnostics segment revenue, comprised of our TRUFORMA, TRUVIEW, and VETGuardian products, was
$0.8 million , up86% over second quarter 2024 revenues, primarily driven by accelerating adoption of our TRUFORMA point-of-care, diagnostic platform and our expanded menu of assays.Therapeutic Device segment revenue, comprised of our PulseVet® and Assisi® products, was
$6.2 million , up8% from second quarter 2024 revenues.
Revenue by Product Category:
Consumable revenues grew to
$5.3 million , up21% over second quarter 2024 revenues, driven primarily by accelerating adoption of our TRUFORMA products and the continued, strong sales of PulseVet® trodes, from both new device installations and reorders associated with existing systems. We anticipate that this growth will further compound and recur in future periods as more devices are installed.Capital revenues were
$1.7 million , flat to second quarter 2024 revenues.
Gross margin was
*Reported financial metrics, including year-over-year and sequential percentage changes, are calculated using actual results, which may not match calculations done using the figures shown in this press release due to rounding. Please refer to the Company's Form 10-Q for additional details.
2025 Second Quarter Results Review
Revenue for the three months ended June 30, 2025, was
Margins remained strong at
Total operating expenses were
Research and development expenses were
Selling and marketing expenses were
General and administrative expenses were
Net loss for the three months ended June 30, 2025 was
*Non-GAAP EBITDA loss (which includes adjustments for stock compensation) for the three months ended June 30, 2025, was
When adjusting for the non-recurring items noted above and other non-cash items, **Adjusted Non-GAAP EBITDA loss was
Liquidity and Outstanding Share Capital
Zomedica had cash, cash equivalents, and available-for-sale securities of
As of June 30, 2025, Zomedica had 979,949,668 common shares issued and outstanding.
For complete financial results, please see Zomedica's filings on EDGAR and SEDAR+ or visit the Zomedica website at www.zomedica.com.
For percentage calculations please refer to the financial statements filed with the SEC on Wednesday, August 6, 2025, along with other public filings.
Zomedica's Fourth Friday at Four Webinar:
Zomedica Corp. is pleased to announce the next installment of its Fourth Friday at Four Webinar series, scheduled for Friday, August 22, 2025 at 4:00 PM ET, during which we will also review and discuss our second quarter financial performance.
For more information visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices, along with the TRUFORMA® diagnostic platform, TRUVIEW® digital cytology system, VETGuardian® no-touch monitoring system, and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
Non-GAAP Measures
Non-GAAP EBITDA, Adjusted Non-GAAP EBITDA, and other measures presented on an adjusted basis are not recognized terms under U.S. GAAP and do not purport to be alternatives to the most comparable U.S. GAAP amounts. Since all companies do not use identical calculations, our definition and presentation of these measures may not be comparable to similarly titled measures reported by other companies. Management uses the identified non-GAAP measures to evaluate the operating performance of the Company and its business segments and to forecast future periods. Management believes these non-GAAP measures assist investors and other interested parties in evaluating Zomedica's on-going operations and provide important supplemental information to management and investors regarding financial and business trends relating to Zomedica's financial condition and results of operations. Investors should not consider these non-GAAP measures as alternatives to the related GAAP measures. Reconciliations of non-GAAP measures to their closest U.S. GAAP equivalent are presented below.
* Non-GAAP EBITDA is defined as net loss and comprehensive loss excluding amortization, depreciation, non-cash stock compensation, and taxes while reversing out the benefits derived from net interest income.
** Non-GAAP Adjusted EBITDA is defined as Non-GAAP EBITDA, as defined above, excluding impairment charges and non-recurring items; including but not limited to specialized accounting, tax, and audit services, new facility integration / start-up costs, and other one-time items.
ZOMEDICA CORP.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Three Months Ended June 30, | ||||||||
2025 | 2024 | |||||||
Net loss and comprehensive loss | $ | (7,353 | ) | $ | (23,980 | ) | ||
Amortization expense | 1,412 | 1,626 | ||||||
Depreciation expense | 509 | 351 | ||||||
Stock-compensation expense | 260 | 858 | ||||||
Interest income | (629 | ) | (1,038 | ) | ||||
Income tax benefit | 12 | (143 | ) | |||||
Non-GAAP EBITDA loss | $ | (5,789 | ) | $ | (22,326 | ) | ||
Impairment expense | - | 16,024 | ||||||
Proforma adjustments (1) | 279 | 1,083 | ||||||
Adjusted Non-GAAP EBITDA loss | $ | (5,510 | ) | $ | (5,219 | ) | ||
(1) Proforma adjustments for the three months ended June 30, 2025 included
ZOMEDICA CORP.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Six Months Ended June 30, | ||||||||
2025 | 2024 | |||||||
Net loss and comprehensive loss | $ | (71,118 | ) | $ | (33,203 | ) | ||
Amortization expense | 3,105 | 3,223 | ||||||
Depreciation expense | 1,030 | 685 | ||||||
Stock-compensation expense | 878 | 1,959 | ||||||
Interest income | (1,359 | ) | (2,131 | ) | ||||
Income tax benefit | (45 | ) | (309 | ) | ||||
Non-GAAP EBITDA loss | $ | (67,509 | ) | $ | (29,776 | ) | ||
Impairment expense | 55,833 | 16,024 | ||||||
Proforma adjustments (1) | 422 | 3,276 | ||||||
Adjusted Non-GAAP EBITDA loss | $ | (11,254 | ) | $ | (10,476 | ) | ||
(1) Proforma adjustments for the six months ended June 30, 2025 included
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What was Zomedica's (ZOMDF) revenue growth in Q2 2025?
How much cash does Zomedica (ZOMDF) have as of Q2 2025?
What was Zomedica's (ZOMDF) gross margin in Q2 2025?
How did Zomedica's Diagnostics segment perform in Q2 2025?
What was Zomedica's (ZOMDF) net loss in Q2 2025?
How did Zomedica's international sales perform in Q2 2025?
